glp-1 drugs eli lilly Orforglipron: Lilly's New Oral Weight-loss Pill Lilly to Boost Obesity Drug
Description
41 The significant reduction in urinary oxalate excretion after weight loss through GLP-based therapies could possibly be attributed to decreased intake of oxalate and oxalate precursors or to reduced hepatic oxalate synthesis
Severe or persistent nausea is not always the medication
Average weight loss in studies is helpful for understanding trends, but individuals vary
Save Hours of Time
Yes, patients can transition between different forms of semaglutide
doi: 10.1016/j.jacc.2025.03.009
